This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
Sharf, MD, and colleagues will discuss treatment considerations in metastatic ER+ breast cancer at the 2024 SABCS meeting.
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Retesting biomarkers is crucial when cancer progression deviates from expected patterns. An expert discusses the next steps ...
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
One in nine New Zealand women get breast cancer in their lifetimes, and around 16% of metastatic breast cancers are ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...